Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigimadlin PK and Safety in Newly Diagnosed Glioblastoma
NCT05376800Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of brigimadlin in glioblastoma (GBM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Total concentration of BI 907828 in brain tissue homogenate up to 24 hours, Calculated unbound concentration of BI 907828 in brain tissue homogenate up to 24 hours and 2 more. Started Nov 2022; status: completed.
02
Drugs
brigimadlin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05376800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376800.